Starting July 1, 2026, Medicare will provide eligible seniors access to FDA-approved weight-loss drugs — Wegovy, Zepbound, and Foundayo — for a flat $50 monthly copay through the new Medicare GLP-1 Bridge program. For seniors currently paying $800–$1,400 per month out of pocket, this is the most significant prescription drug development in years.
What Is the Medicare GLP-1 Bridge?
The GLP-1 Bridge is a CMS demonstration running July 1, 2026 through December 31, 2027. Medicare pays the difference between the drug’s retail price and your $50 copay — saving qualifying seniors up to $15,600 per year on Wegovy alone.
Which Drugs Are Covered?
- Wegovy (semaglutide injection) — weekly shot, retail ~$1,350/month, saves ~$1,300/month
- Zepbound KwikPen (tirzepatide) — weekly shot, retail ~$1,060/month, saves ~$1,010/month
- Foundayo (oral semaglutide pill) — daily pill, retail ~$400/month, saves ~$350/month
Important: Ozempic is NOT covered for weight loss — it is FDA-approved for Type 2 diabetes only, not obesity.
Who Qualifies for the $50 Copay?
| Requirement | Details |
|---|---|
| Medicare enrollment | Must be enrolled in a Medicare Part D plan |
| BMI | 27 or higher |
| Qualifying condition | Heart disease, prediabetes, high blood pressure, high cholesterol, sleep apnea, or osteoarthritis |
| Valid prescription | From a licensed provider for Wegovy, Zepbound, or Foundayo |
Critical Warning: The $50 Does NOT Count Toward Your Out-of-Pocket Cap
Your $50 monthly copay does not count toward your Part D deductible or your $2,100 annual out-of-pocket cap. Your other drug costs are completely unaffected. Plan your total spending accordingly.
Step-by-Step: How to Access This Benefit
- Confirm Part D enrollment at Medicare.gov or call 1-800-MEDICARE
- Visit your doctor — get BMI documented and a qualifying condition on record
- Request a prescription specifically for Wegovy, Zepbound, or Foundayo under the GLP-1 Bridge
- Fill after July 1, 2026 — the $50 cap only applies after the program launch date
- Use a participating pharmacy — CVS, Walgreens, Walmart, and most major chains participate
What the Research Shows for Seniors
The landmark SELECT trial showed semaglutide reduced major cardiovascular events — heart attack and stroke — by 20% in adults with obesity and existing cardiovascular disease. For seniors with elevated heart risk, this protective benefit is as important as the weight-loss effect. Tirzepatide (Zepbound) additionally reduces sleep apnea severity by up to 63%, directly benefiting the estimated 18 million seniors with the condition.
Will This Program Become Permanent?
The GLP-1 Bridge runs through December 2027. The BALANCE Act in Congress would establish permanent Medicare GLP-1 coverage. Seniors who benefit are encouraged to contact their congressional representatives in support of permanent coverage. AARP is actively advocating for this legislation.
Sources
